- Home
- NRIX vs TIXT Comparison
NRIX vs TIXT Comparison
Compare NRIX & TIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- TIXT
- Stock Information
- Founded
- NRIX 2009
- TIXT 2005
- Country
- NRIX United States
- TIXT Canada
- Employees
- NRIX N/A
- TIXT N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- TIXT EDP Services
- Sector
- NRIX Health Care
- TIXT Technology
- Exchange
- NRIX Nasdaq
- TIXT Nasdaq
- Market Cap
- NRIX 1.1B
- TIXT 694.9M
- IPO Year
- NRIX 2020
- TIXT 2021
- Fundamental
- Price
- NRIX $9.64
- TIXT $2.64
- Analyst Decision
- NRIX Strong Buy
- TIXT Hold
- Analyst Count
- NRIX 17
- TIXT 8
- Target Price
- NRIX $30.71
- TIXT $4.44
- AVG Volume (30 Days)
- NRIX 999.6K
- TIXT 220.4K
- Earning Date
- NRIX 04-08-2025
- TIXT 05-09-2025
- Dividend Yield
- NRIX N/A
- TIXT N/A
- EPS Growth
- NRIX N/A
- TIXT N/A
- EPS
- NRIX N/A
- TIXT N/A
- Revenue
- NRIX $56,417,000.00
- TIXT $2,658,000,000.00
- Revenue This Year
- NRIX $15.73
- TIXT $3.72
- Revenue Next Year
- NRIX N/A
- TIXT $3.63
- P/E Ratio
- NRIX N/A
- TIXT N/A
- Revenue Growth
- NRIX N/A
- TIXT N/A
- 52 Week Low
- NRIX $8.18
- TIXT $2.13
- 52 Week High
- NRIX $29.56
- TIXT $7.74
- Technical
- Relative Strength Index (RSI)
- NRIX 36.33
- TIXT 54.39
- Support Level
- NRIX $11.05
- TIXT $2.46
- Resistance Level
- NRIX $11.56
- TIXT $2.64
- Average True Range (ATR)
- NRIX 0.64
- TIXT 0.10
- MACD
- NRIX -0.04
- TIXT 0.03
- Stochastic Oscillator
- NRIX 18.45
- TIXT 91.38
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.